

Philip L Gordts

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1064522/philip-l-gordts-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45
papers

2,534
citations

20
h-index

50
g-index

53
ext. papers

3,111
ext. citations

10
avg, IF

5.01
L-index

#	Paper	IF	Citations
45	The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection 2021 ,		3
44	Genome-wide screens uncover KDM2B as a modifier of protein binding to heparan sulfate. <i>Nature Chemical Biology</i> , 2021 , 17, 684-692	11.7	4
43	Dietary Neu5Ac Intervention Protects Against Atherosclerosis Associated With Human-Like Neu5Gc Loss-Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , 41, 2730-2739	9.4	0
42	Reply to Soulillou et al.: Difficulties in extrapolating from animal models exemplify unusual human atherosclerosis susceptibility and mechanisms via loss. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 1847-1848	11.5	1
41	ZNF263 is a transcriptional regulator of heparin and heparan sulfate biosynthesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 9311-9317	11.5	11
40	microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production. <i>JCI Insight</i> , 2020 , 5,	9.9	16
39	Statins and increases in Lp(a): an inconvenient truth that needs attention. <i>European Heart Journal</i> , 2020 , 41, 192-193	9.5	13
38	Statin therapy increases lipoprotein(a) levels. <i>European Heart Journal</i> , 2020 , 41, 2275-2284	9.5	134
37	Proteoglycans in Obesity-Associated Metabolic Dysfunction and Meta-Inflammation. <i>Frontiers in Immunology</i> , 2020 , 11, 769	8.4	27
36	ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance. <i>Journal of Lipid Research</i> , 2019 , 60, 1379-1395	6.3	27
35	Triglyceride-rich lipoprotein binding and uptake by heparan sulfate proteoglycan receptors in a CRISPR/Cas9 library of Hep3B mutants. <i>Glycobiology</i> , 2019 , 29, 582-592	5.8	8
34	LRP1 Has a Predominant Role in Production over Clearance of A β in a Mouse Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2019 , 56, 7234-7245	6.2	32
33	Hyaluronan as a potential thermogenic rheostat. <i>Nature Metabolism</i> , 2019 , 1, 503-504	14.6	
32	PID1 regulates insulin-dependent glucose uptake by controlling intracellular sorting of GLUT4-storage vesicles. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019 , 1865, 1592-1603	6.9	8
31	ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 2145-2156	9.4	7
30	Hepatic heparan sulfate is a master regulator of hepcidin expression and iron homeostasis in human hepatocytes and mice. <i>Journal of Biological Chemistry</i> , 2019 , 294, 13292-13303	5.4	9
29	Human species-specific loss of CMP--acetylneuraminic acid hydroxylase enhances atherosclerosis via intrinsic and extrinsic mechanisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 16036-16045	11.5	39

28	Human Cytomegalovirus Replication Is Inhibited by the Autophagy-Inducing Compounds Trehalose and SMER28 through Distinctly Different Mechanisms. <i>Journal of Virology</i> , 2018 , 92,	6.6	12
27	Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism. <i>Current Opinion in Lipidology</i> , 2018 , 29, 171-179	4.4	48
26	The adaptor protein PID1 regulates receptor-dependent endocytosis of postprandial triglyceride-rich lipoproteins. <i>Molecular Metabolism</i> , 2018 , 16, 88-99	8.8	14
25	Deletion of Lymphangiogenic and Angiogenic Growth Factor VEGF-D Leads to Severe Hyperlipidemia and Delayed Clearance of Chylomicron Remnants. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018 , 38, 2327-2337	9.4	18
24	The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis. <i>Matrix Biology</i> , 2018 , 71-72, 262-282	11.4	24
23	Lipoprotein(a) Mass Levels Increase Significantly According to Genotype: An Analysis of 431 239 Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017 , 37, 580-588	9.4	60
22	Guanidynylated Neomycin Conjugation Enhances Intranasal Enzyme Replacement in the Brain. <i>Molecular Therapy</i> , 2017 , 25, 2743-2752	11.7	6
21	Dietary nitrate struggles in atherosclerosis. <i>Atherosclerosis</i> , 2016 , 245, 71-3	3.1	6
20	ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. <i>Journal of Clinical Investigation</i> , 2016 , 126, 2855-66	15.9	134
19	Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I. <i>PLoS ONE</i> , 2016 , 11, e0150850	3.7	15
18	Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development. <i>Nature Communications</i> , 2015 , 6, 6356	17.4	258
17	Biallelic mutations in SNX14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. <i>Nature Genetics</i> , 2015 , 47, 528-34	36.3	89
16	Small molecule antagonists of cell-surface heparan sulfate and heparin-protein interactions. <i>Chemical Science</i> , 2015 , 6, 5984-5993	9.4	19
15	Heparan sulfate proteoglycans fine-tune macrophage inflammation via IFN- γ . <i>Cytokine</i> , 2015 , 72, 118-9	4	15
14	Reducing macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced type I interferon signaling. <i>Cell Metabolism</i> , 2014 , 20, 813-826	24.6	50
13	Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, 2065-74	9.4	53
12	Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2742-51	15.9	54
11	Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance. <i>Hepatology</i> , 2012 , 55, 277-86	11.2	30

10	Impaired LDL receptor-related protein 1 translocation correlates with improved dyslipidemia and atherosclerosis in apoE-deficient mice. <i>PLoS ONE</i> , 2012 , 7, e38330	3.7	20
9	A genetic model of substrate reduction therapy for mucopolysaccharidosis. <i>Journal of Biological Chemistry</i> , 2012 , 287, 36283-90	5.4	16
8	The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles. <i>Journal of Lipid Research</i> , 2012 , 53, 2198-2204	6.3	29
7	Molecular dissection of syndecan-1 mediated triglyceride-rich lipoprotein clearance. <i>FASEB Journal</i> , 2012 , 26, 792.2	0.9	
6	Brown adipose tissue activity controls triglyceride clearance. <i>Nature Medicine</i> , 2011 , 17, 200-5	50.5	1102
5	Knock-in approaches. <i>Methods in Molecular Biology</i> , 2011 , 693, 257-75	1.4	6
4	Generation of a series of knock-in alleles using RMCE in ES cells. <i>Methods in Molecular Biology</i> , 2011 , 693, 277-81	1.4	4
3	Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis. <i>Circulation Research</i> , 2010 , 106, 1624-34	15.7	39
2	Inactivation of the proximal NPXY motif impairs early steps in LRP1 biosynthesis. <i>Cellular and Molecular Life Sciences</i> , 2010 , 67, 135-45	10.3	24
1	Inactivation of the LRP1 intracellular NPxYxxL motif in LDLR-deficient mice enhances postprandial dyslipidemia and atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 1258-64	9.4	36